Synopsis:
Yasons Chemex Care reported Rs. 49.3 crore revenue in H1 FY26, up 68 percent YoY; net profit Rs. 1.01 crore, recovering sequentially but down 46 percent YoY.
During Tuesday’s trading session, shares of a company trading chemicals and manufacturing of dyes and intermediates and FMCG Products surged nearly 7 percent on NSE, after reporting financial results for H1 FY26 with a revenue growth of around 5 percent HoH and 68 percent YoY.
At 11:16 a.m., the shares of Yasons Chemex Care Limited were trading in the green at Rs. 13.15 on NSE, up by around 1.2 percent, as against its previous closing price of Rs. 13, with a market cap of Rs. 25.4 crores. The stock hit its 52-week high at Rs. 23.5 on 8th November 2024, and is trading at a discount of around 44 percent from its current price levels.
What’s the News
Yasons Chemex Care Limited announced the financial results for the first half of FY26 (H1 FY26) on Monday, post-market hours, as per its latest regulatory filings with the NSE.
For H1 FY26, the company reported a consolidated revenue from operations of Rs. 49.3 crores, reflecting a sequential growth of around 5 percent HoH compared to Rs. 47 crores in H2 FY25, and a year-on-year increase of nearly 68 percent from Rs. 29.4 crores recorded in H1 FY25.
During the same period, net profit stood at Rs. 1.01 crores, indicating a notable recovery from a net loss of Rs. 0.26 crores in H2 FY25. However, on a year-on-year basis, the company’s net profit declined by around 46 percent from Rs. 1.87 crores reported in H1 FY25.
Yasons Chemex Care Limited, a subsidiary of Yash Chemex Limited, is engaged primarily in the business of trading of chemicals and manufacturing of dyes and intermediates and FMCG products like hand sanitisers, hair oil, soap, perfumes, deodorants, etc. The company has a manufacturing plant located in the state of Gujarat.
Written by Shivani Singh
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
